SBRT plus systemic therapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding targeted radiation therapy (SBRT) to standard systemic therapy helps people with advanced liver cancer live longer compared to systemic therapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have advanced liver cancer (BCLC stage C) that has spread to the main liver vein or to other organs.
- You have not had any systemic cancer treatment (like pills or IV therapy) for this current liver cancer.
- Your liver function is good enough (Child-Pugh score 7 or less).
- You are able to take care of yourself and be out of bed for at least part of the day.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This early-phase trial tests a treatment plan that combines focused radiation with two medicines—an immunotherapy drug and an anti-angiogenesis drug—to treat hepatocellular carcinoma (liver cancer). It may help shrink tumors or control disease when surgery or ablation can’t be used, and when systemic (whole-body) treatment is needed.
This trial tests whether combining the immunotherapy drug sintilimab with targeted radiation therapy before surgery can improve outcomes for patients with liver cancer that can be surgically removed. It aims to shrink the tumor and reduce the chance of recurrence.
This trial tests a combination of radiation therapy (SBRT), an immunotherapy drug (camrelizumab), and a targeted therapy drug (apatinib) to shrink liver cancer that cannot be removed with surgery. The goal is to make the cancer small enough for surgery later.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.